NCT04204057View on ClinicalTrials.gov

Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 28, 2019

Primary Completion Date

October 2, 2020

Study Completion Date

October 2, 2020

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell

Interventions

DRUG

Tenalisib

Tenalisib 800 mg BID, Orally

Trial Locations (6)

1431

"University Multiprofile Hospital for Active Treatment Sv Ivan Rilski Ltd", Sofia

5800

"University Multiprofile Hospital for Active Treatment Dr Georgi Stranski Ltd.,", Pleven

Unknown

Ltd. M.Zodelava Hematology Centre, Tbilisi

Medivest - Institute of Hematology and Transfusiology, Tbilisi

Voivodship Multi-Specialist Center for Oncology and Traumatology M. Copernicus, Lodz

41-503

Silesian Healthy Blood Clinic Grosicki, Grosicka Sp.J., Chorzów

All Listed Sponsors

lead

Rhizen Pharmaceuticals SA

INDUSTRY

NCT04204057 - Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) | Biotech Hunter | Biotech Hunter